Unilever Earnings: 3 Big Takeaways
Here are the highlights from the consumer products giant's latest report.
3 Top Stocks Under $5
Groupon, Trivago, and Fitbit have prospects that are more promising than their low share prices.
5G Is Rescuing These Top Semiconductor Stocks From the Trade War
The 5G revolution is trumping the U.S.-China trade war for this market-beating tech sector.
Which stock wins between these two biotechs?
With a new decade nearly here, it’s time to look back on the biggest and best investing trends of the last 10 years.
The collaboration-software maker delivered solid results, but investors were looking for more.
The iPhone maker spends $15 billion a year on new products and services.
It's even more than you think.
The top titanium dioxide manufacturer has seen its shares tumble. Is it now a bargain?
Azure's ascent has driven the software giant's stock to lofty heights. Can its impressive gains continue?
This Atlantic-based grower has all the tools necessary to deliver the green.
Softbank's misjudgment with the office-sharing start-up isn't unique and it's having a detrimental effect on Grubhub and Uber.
Are you conservative or are you really conservative? Picking one of these two midstream income stocks is actually a tough call.
That's the end of an expensive business ethics investigation that started way back in 2013.
New CEO Mark Tritton may be able to improve Bed Bath & Beyond's product assortment -- but that probably won't be enough to spur a Target-like rejuvenation for the struggling home-goods chain.
The drumbeat of negative news may cause cigarettes to actually seem like the safer alternative.
Let's compare the risk and reward profiles of these two aviation giants.
You can't fund an HSA if you're enrolled in Medicare, but that doesn't mean you can't use an existing one once your Medicare coverage begins.
Illicit pot production continues to dominate legal weed sales, even with Canada and select states legalizing cannabis.
Azure and Office 365 are a powerful combination.
BridgeBio announced this week that it had terminated its effort to acquire the remaining stake in subsidiary Eidos Therapeutics. What does this mean for Eidos shareholders?
Can this struggling stock get back on track next week?
The company's most promising aircraft suffers a rough landing, but it doesn't crash the bull case for Kratos.